Clinical Trial Update: Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of a Cutaneous Leishmaniasis vaccine using recombinant human interleukin-12 and aluminum hydroxide gel as adj…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• aluminum hydroxide gel (aluminum hydroxide gel)
• recombinant human interleukin-12 (interleukin-12)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cutaneous Leishmaniasis | Phase 1 | Status: COMPLETED